cqframework · brynrhodes · Nov 10, 2022 · Nov 10, 2022
diff --git a/input/resources/activitydefinition/activitydefinition-opioidcds-risk-assessment-request.xml b/input/resources/activitydefinition/activitydefinition-opioidcds-risk-assessment-request.xml
@@ -31,7 +31,7 @@
     </jurisdiction>
     <purpose value="Provides dynamic risk assessment suggestion as part of recommendation 7 workflow."/>
     <usage value="Used to create a risk assessment ServiceRequest when the inclusion criteria is satisfied for recommendation 7."/>
-    <copyright value="© CDC 2022+."/>
+    <copyright value="© CDC 2016+."/>
     <topic>
         <coding>
             <system value="http://terminology.hl7.org/CodeSystem/definition-topic"/>

diff --git a/input/resources/activitydefinition/activitydefinition-opioidcds-urine-screening-request.xml b/input/resources/activitydefinition/activitydefinition-opioidcds-urine-screening-request.xml
@@ -31,7 +31,7 @@
     </jurisdiction>
     <purpose value="Provides urine screening suggestion as part of opioid prescribing clinical decision support."/>
     <usage value="Used to create a urine screening ServiceRequest."/>
-    <copyright value="© CDC 2022+."/>
+    <copyright value="© CDC 2016+."/>
     <topic>
         <coding>
             <system value="http://terminology.hl7.org/CodeSystem/definition-topic"/>

diff --git a/input/resources/plandefinition/opioidcds-01.json b/input/resources/plandefinition/opioidcds-01.json
@@ -531,7 +531,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-02.json b/input/resources/plandefinition/opioidcds-02.json
@@ -613,7 +613,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-03-patient-view.json b/input/resources/plandefinition/opioidcds-03-patient-view.json
@@ -622,7 +622,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Providers should use caution when prescribing extended-release/long-acting (ER/LA) opioids as they carry a higher risk and negligible benefit compared to immediate-release opioids.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-03.json b/input/resources/plandefinition/opioidcds-03.json
@@ -598,7 +598,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Providers should use caution when prescribing extended-release/long-acting (ER/LA) opioids as they carry a higher risk and negligible benefit compared to immediate-release opioids.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-04-05.json b/input/resources/plandefinition/opioidcds-04-05.json
@@ -683,7 +683,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Providers should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when considering increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage to >90 MME/day",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-06.json b/input/resources/plandefinition/opioidcds-06.json
@@ -499,7 +499,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-07.json b/input/resources/plandefinition/opioidcds-07.json
@@ -716,7 +716,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-08-order-sign.json b/input/resources/plandefinition/opioidcds-08-order-sign.json
@@ -823,7 +823,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-08.json b/input/resources/plandefinition/opioidcds-08.json
@@ -823,7 +823,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-09.json b/input/resources/plandefinition/opioidcds-09.json
@@ -553,7 +553,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-10-order-sign.json b/input/resources/plandefinition/opioidcds-10-order-sign.json
@@ -770,7 +770,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Providers should be aware if patients are taking other prescription drugs or illicit drugs that might increase their risk of an overdose.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-10-patient-view.json b/input/resources/plandefinition/opioidcds-10-patient-view.json
@@ -794,7 +794,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Providers should be aware if patients are taking other prescription drugs or illicit drugs that might increase their risk of an overdose.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-10.json b/input/resources/plandefinition/opioidcds-10.json
@@ -770,7 +770,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Providers should be aware if patients are taking other prescription drugs or illicit drugs that might increase their risk of an overdose.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-11-patient-view.json b/input/resources/plandefinition/opioidcds-11-patient-view.json
@@ -576,7 +576,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Clinicians should avoid prescribing opioid pain medication and benzodiazepines or other central nervous system depressant concurrently whenever possible.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-11.json b/input/resources/plandefinition/opioidcds-11.json
@@ -627,7 +627,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Clinicians should avoid prescribing opioid pain medication and benzodiazepines or other central nervous system depressant concurrently whenever possible.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/resources/plandefinition/opioidcds-12-patient-view.json b/input/resources/plandefinition/opioidcds-12-patient-view.json
@@ -403,7 +403,7 @@
   } ],
   "purpose": "CDC's Guideline for Prescribing Opioids for Subacute or Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.",
   "usage": "Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone) for patients with opioid use disorder.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "topic": [ {
     "text": "Opioid Prescribing"
   } ],

diff --git a/input/vocabulary/valueset/valueset-benzodiazepine-medications.json b/input/vocabulary/valueset/valueset-benzodiazepine-medications.json
@@ -56,7 +56,7 @@
     } ]
   } ],
   "purpose": "Benzodiazepine medications for opioid management",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "expansion": {
     "identifier": "6758d93c-2361-4f04-abad-40015a0d557a",
     "timestamp": "2022-05-09T13:03:22-06:00",

diff --git a/input/vocabulary/valueset/valueset-buprenorphine-and-methadone-medications.json b/input/vocabulary/valueset/valueset-buprenorphine-and-methadone-medications.json
@@ -56,7 +56,7 @@
     } ]
   } ],
   "purpose": "Buprenorphine and Methadone medications for opioid management",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://www.nlm.nih.gov/research/umls/rxnorm",

diff --git a/input/vocabulary/valueset/valueset-cdc-malignant-cancer-conditions.json b/input/vocabulary/valueset/valueset-cdc-malignant-cancer-conditions.json
@@ -56,7 +56,7 @@
     } ]
   } ],
   "purpose": "Cancer conditions to be used as an exclusion for opioid management review",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://hl7.org/fhir/sid/icd-10-cm",

diff --git a/input/vocabulary/valueset/valueset-cocaine-urine-drug-screening-tests.json b/input/vocabulary/valueset/valueset-cocaine-urine-drug-screening-tests.json
@@ -50,7 +50,7 @@
     } ]
   } ],
   "purpose": "Identification of urine drug tests where results can be used when considering pain management therapy",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "expansion": {
     "identifier": "13682c93-b63e-4e91-aabb-8e92ceaaf9ab",
     "timestamp": "2022-05-09T13:00:29-06:00",

diff --git a/input/vocabulary/valueset/valueset-conditions-documenting-substance-misuse.json b/input/vocabulary/valueset/valueset-conditions-documenting-substance-misuse.json
@@ -44,7 +44,7 @@
     } ]
   } ],
   "purpose": "Identification of patients that have a documented substance misuse condition now or in the past when considering opioid therapy.",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://snomed.info/sct",

diff --git a/input/vocabulary/valueset/valueset-conditions-likely-terminal-for-opioid-prescribing.json b/input/vocabulary/valueset/valueset-conditions-likely-terminal-for-opioid-prescribing.json
@@ -56,7 +56,7 @@
     } ]
   } ],
   "purpose": "Conditions for exclusions in CDC 2022 Opioid Guideline",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://hl7.org/fhir/sid/icd-10-cm",

diff --git a/...ocabulary/valueset/valueset-extended-release-opioid-with-ambulatory-misuse-potential.json b/...ocabulary/valueset/valueset-extended-release-opioid-with-ambulatory-misuse-potential.json
@@ -59,7 +59,7 @@
     } ]
   } ],
   "purpose": "Identify medication orders for long-acting opioids",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "expansion": {
     "identifier": "5726ab61-d902-4519-870b-5012db6284af",
     "timestamp": "2022-05-09T13:00:29-06:00",

diff --git a/input/vocabulary/valueset/valueset-fentanyl-type-medications.json b/input/vocabulary/valueset/valueset-fentanyl-type-medications.json
@@ -46,7 +46,7 @@
       "code": "US"
     } ]
   } ],
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "expansion": {
     "identifier": "559d8b02-03c1-4f1b-9337-4d0f6caacd2a",
     "timestamp": "2022-05-09T13:00:29-06:00",

diff --git a/input/vocabulary/valueset/valueset-fentanyl-type-urine-drug-screening-tests.json b/input/vocabulary/valueset/valueset-fentanyl-type-urine-drug-screening-tests.json
@@ -43,7 +43,7 @@
       "code": "US"
     } ]
   } ],
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://loinc.org",

diff --git a/input/vocabulary/valueset/valueset-general-opiate-urine-drug-screening-tests.json b/input/vocabulary/valueset/valueset-general-opiate-urine-drug-screening-tests.json
@@ -53,7 +53,7 @@
     } ]
   } ],
   "purpose": "Identification of urine drug tests where results can be used when considering pain management therapy",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "expansion": {
     "identifier": "37c90ea1-de62-441d-b69f-925dd8e21817",
     "timestamp": "2022-05-09T13:00:29-06:00",

diff --git a/input/vocabulary/valueset/valueset-hospice-finding.json b/input/vocabulary/valueset/valueset-hospice-finding.json
@@ -53,7 +53,7 @@
     } ]
   } ],
   "purpose": "Initially created to identify conditions for exclusions in CDC 2022 Opioid Guideline",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://snomed.info/sct",

diff --git a/input/vocabulary/valueset/valueset-hospice-procedure.json b/input/vocabulary/valueset/valueset-hospice-procedure.json
@@ -49,7 +49,7 @@
       "code": "US"
     } ]
   } ],
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://snomed.info/sct",

diff --git a/input/vocabulary/valueset/valueset-limited-life-expectancy-conditions.json b/input/vocabulary/valueset/valueset-limited-life-expectancy-conditions.json
@@ -56,7 +56,7 @@
     } ]
   } ],
   "purpose": "Provide terminology for conditions to be used as exclusions for opioid use recommendations",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://snomed.info/sct",

diff --git a/input/vocabulary/valueset/valueset-naloxone-medications.json b/input/vocabulary/valueset/valueset-naloxone-medications.json
@@ -56,7 +56,7 @@
     } ]
   } ],
   "purpose": "Naloxone medications for opioid management",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://www.nlm.nih.gov/research/umls/rxnorm",

diff --git a/input/vocabulary/valueset/valueset-non-opioid-drug-urine-screening.json b/input/vocabulary/valueset/valueset-non-opioid-drug-urine-screening.json
@@ -44,7 +44,7 @@
     } ]
   } ],
   "purpose": "Identification of non-opioid urine drug tests where rusults can be used when considering opioid therapy",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://loinc.org",

diff --git a/input/vocabulary/valueset/valueset-non-synthetic-opioid-medications.json b/input/vocabulary/valueset/valueset-non-synthetic-opioid-medications.json
@@ -46,7 +46,7 @@
       "code": "US"
     } ]
   } ],
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "expansion": {
     "identifier": "a5f5cd26-090e-40b6-871e-242eea85be23",
     "timestamp": "2022-05-09T13:00:29-06:00",

diff --git a/input/vocabulary/valueset/valueset-oncology-specialty-designations.json b/input/vocabulary/valueset/valueset-oncology-specialty-designations.json
@@ -56,7 +56,7 @@
     } ]
   } ],
   "purpose": "Provider types used to identify cancer care related encounters",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://nucc.org/provider-taxonomy",

diff --git a/input/vocabulary/valueset/valueset-opiate-specific-urine-drug-screening-tests.json b/input/vocabulary/valueset/valueset-opiate-specific-urine-drug-screening-tests.json
@@ -53,7 +53,7 @@
     } ]
   } ],
   "purpose": "Identification of urine drug tests where results can be used when considering pain management therapy",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "expansion": {
     "identifier": "d257ac37-d2ab-4445-80b1-e06dd367f46e",
     "timestamp": "2022-05-09T13:00:29-06:00",

diff --git a/input/vocabulary/valueset/valueset-opioid-analgesics-with-ambulatory-misuse-potential.json b/input/vocabulary/valueset/valueset-opioid-analgesics-with-ambulatory-misuse-potential.json
@@ -59,7 +59,7 @@
     } ]
   } ],
   "purpose": "Opioid medications that should have opioid management CDS",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "expansion": {
     "identifier": "33bc1977-428c-44cd-9be7-c2568cbed1f9",
     "timestamp": "2022-05-09T13:03:22-06:00",

diff --git a/input/vocabulary/valueset/valueset-opioid-counseling-procedure.json b/input/vocabulary/valueset/valueset-opioid-counseling-procedure.json
@@ -44,7 +44,7 @@
     } ]
   } ],
   "purpose": "Identify a procedure for opioid use couseling to the patient",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://snomed.info/sct",

diff --git a/input/vocabulary/valueset/valueset-opioid-drug-urine-screening.json b/input/vocabulary/valueset/valueset-opioid-drug-urine-screening.json
@@ -44,7 +44,7 @@
     } ]
   } ],
   "purpose": "Identification of opioid urine drug tests where rusults can be used when considering opioid therapy",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://loinc.org",

diff --git a/input/vocabulary/valueset/valueset-opioid-misuse-assessment-procedure.json b/input/vocabulary/valueset/valueset-opioid-misuse-assessment-procedure.json
@@ -44,7 +44,7 @@
     } ]
   } ],
   "purpose": "Risk assessment to occur when considering opioid therapy",
-  "copyright": "© CDC 2022+.",
+  "copyright": "© CDC 2016+.",
   "compose": {
     "include": [ {
       "system": "http://snomed.info/sct",